CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

1 Views
administrator
administrator
07/07/23

Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab vs placebo + atezolizumab in patients with PD-L1-selected NSCLC.

Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next